CCNU, melphalan, methotrexate, and prednisone (CAMP) versus cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in the treatment of advanced breast cancer in postmenopausal women.
作者信息
Salimtschik M, Snel S, Havsteen H, Dombernowsky P, Mouridsen H T
出版信息
Cancer Treat Rep. 1980 Apr-May;64(4-5):635-7.
PMID:7000346
Abstract
Sixty-nine postmenopausal patients with advanced breast cancer were randomized to receive treatment with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) or CCNU, melphalan, methotrexate, and prednisone (CAMP). Response rate (partial and complete remission) was significantly higher with CMF (50%) than with CAMP (20%). Hematologic toxic effects were equally pronounced with the two combinations as were the other side effects with the exception of alopecia, which occurred most frequently with CMF.
摘要
相似文献
1
2
Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cancer. 2002 Jul 15;95(2):228-35. doi: 10.1002/cncr.10678.
3
4
Recent progress in breast cancer management. Combined modality (adjuvant) therapy.
Arch Intern Med. 1981 Jul;141(8):1055-9.
5
[Treatment of advanced breast cancer with cyclophosphamide, methotrexate, 5-fluorouracil and prednisone (CMFP)].
Medicina (B Aires). 1981;41(1):65-70.
6
7
Evaluation of single-drug versus multiple-drug chemotherapy in the treatment of advanced breast cancer.
Cancer Treat Rep. 1977 Jan-Feb;61(1):47-50.
8
Combination chemotherapy with CCNU, melphalan, methotrexate, and prednisone (CAMP) in 35 patients with advanced breast cancer.
Cancer Treat Rep. 1977 Nov;61(8):1603-5.
9
10
CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial.
Eur J Cancer (1965). 1980;Suppl 1:119-23.
Zotero 插件